P392
|
Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab ± ipilimumab: CheckMate 142
|
Scott Kopetz1, Vittorina Zagonel2, Michael J. Overman1, Ray McDermott3, Michael A. Morse4, Franklin L. Chen5, James Lee6, Rebecca A. Moss7, Lilan Ling8, Alexander Greenfield7, Danielle Greenawalt7, Z. Alexander Cao7
|
1MD Anderson Cancer Center, Houston, TX, USA 2Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy 3St. Vincent's University, Dublin, Ireland 4Duke University Medical Center, Durham, NC, USA 5Novant Health Oncology Specialists, Winston-Salem, NC, USA 6University of Pittsburgh School of Medicine UPMC, Pittsburgh, PA, USA 7Bristol-Myers Squibb, Princeton, NJ, USA 8Memorial Sloan-Kettering Cancer Center, New York, NY, USA
|
Microbiome | Checkpoint blockade | Clinical study | Solid tumors
|
P393
|
Association of Microbiome to Nivolumab Response in Metastatic Renal Cell Carcinoma (mRCC)
|
Manuel Maia1, Valeriy Poroyko1, Hae Won2, Paulo Bergerot1, Lorena Almeida1, Nazli Dizman1, JoAnn Hsu1, Jeremy Jones2, Ravi Salgia1, Sumanta Pal1
|
1City of Hope Comprehensive Cancer Center, Duarte, CA, USA 2Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
|
Checkpoint blockade | Microbiome
|
P394
|
Commensal microbiota associated with anti-PD-1 efficacy in metastatic melanoma patients
|
Vyara Matson1, Jessica Fessler1, Riyue Bao1, Tara Chongsuwat1, Yuanyuan Zha1, Maria-Luisa Alegre1, Jason Luke1, Thomas Gajewski1
|
1University of Chicago, Chicago, IL, USA
|
Microbiome | Biomarkers | Clinical study | Solid tumors | Tumor infiltrating lymphocytes (TILs)
|